AI Verdict
RANI has stronger fundamentals based on our AI analysis.
RANI vs RANGU Fundamental Comparison
| Metric | RANI | RANGU |
|---|---|---|
| Revenue | $1.6M | N/A |
| Net Income | $-29.7M | $4.0M |
| Net Margin | -1,817.1% | N/A |
| ROE | -89.9% | 1,915.3% |
| ROA | -50.6% | 3.3% |
| Current Ratio | 4.21x | N/A |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $-0.45 | $-0.01 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RANI vs RANGU: Frequently Asked Questions
Is RANI or RANGU a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RANI has stronger fundamentals. RANI is rated SELL (48% confidence) while RANGU is rated STRONG SELL (88% confidence). This is not investment advice.
How does RANI compare to RANGU fundamentally?
Rani Therapeutics Holdings, Inc. has ROE of -89.9% vs Range Capital Acquisition Corp.'s 1,915.3%. Net margins are -1,817.1% vs N/A respectively.
Which stock pays higher dividends, RANI or RANGU?
RANI has a dividend yield of N/A or no dividend while RANGU has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RANI or RANGU for long term?
For long-term investing, consider that RANI has SELL rating with 48% confidence, while RANGU has STRONG SELL rating with 88% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RANI vs RANGU?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RANI vs RANGU, the AI consensus favors RANI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.